Liquidia (LQDA) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is LQDA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Liquidia kept the right to market YUTREPIA for PAH after the settlement with United Therapeutics. This settlement limits YUTREPIA's potential in PH-ILD, but since it can still be sold to patients using it and to patients…

Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.…

Liquidia reports surging YUTREPIA sales, record October shipments and expanding PAH adoption amid post-settlement market changes and referral disruptions.…

Liquidia Corporation (NASDAQ: LQDA - Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday following a better than expected earnings announcement. The stock has a 50 day moving average…

Liquidia NASDAQ: LQDA reported a 31% sequential increase in third-quarter YUTREPIA sales as the company sought to reassure investors that its pulmonary arterial hypertension business can continue growing following a pate…

Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript…

Liquidia Corporation (LQDA) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to a loss of $0.04 per share a year ago.…

MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Offi…

MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and v…

MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and v…

LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.…

Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) investors concernin…

Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.…

Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust dis…

A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.…

U.S. stocks were mostly lower, with the Nasdaq Composite falling around 200 points on Wednesday.…

Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.…

MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and v…

Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litigati…

Liquidia Corporation (NASDAQ: LQDA - Get Free Report)'s stock price gapped up prior to trading on Monday. The stock had previously closed at $27.38, but opened at $29.27. Liquidia shares last traded at $29.0220, with a v…

A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations A reported 57% plunge followed a court f…

LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.…

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Liquidia (LQDA) To Contact Him Directly To Discuss Their Options…

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). The investigation concerns whet…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

